Pfizer Aktie 962004 / US7170811035
22.28
CHF
0.43
CHF
1.94%
20.11.2024
BRX
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Pfizer Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | Pfizer Inc. | 5.73 | 1.65 | USD |
| 2022 | Pfizer Inc. | 3.14 | 1.61 | USD |
| 2021 | Pfizer Inc. | 2.66 | 1.57 | USD |
| 2020 | Pfizer Inc. | 4.16 | 1.53 | USD |
| 2019 | Pfizer Inc. | 3.73 | 1.46 | USD |
| 2018 | Pfizer Inc. | 3.16 | 1.38 | USD |
| 2017 | Pfizer Inc. | 3.59 | 1.30 | USD |
| 2016 | Pfizer Inc. | 3.76 | 1.22 | USD |
| 2015 | Pfizer Inc. | 3.53 | 1.14 | USD |
| 2014 | Pfizer Inc. | 3.40 | 1.06 | USD |
Gewinn je Aktie- Pfizer
| 3.5 17 | 1.9 18 | 2.9 19 | 1.7 20 | 3.8 21 | 5.5 22 | 0.4 23 |
Umsatz je Aktie- Pfizer
| 8.7 17 | 9.0 18 | 9.1 19 | 7.4 20 | 14.2 21 | 17.5 22 | 10.2 23 |
KGV- Pfizer
| 10.3 17 | 23.4 18 | 13.7 19 | 21.6 20 | 15.2 21 | 9.4 22 | 76.7 23 |
Pfizer Inc.: Die Aktie (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 3.52 | 1.87 | 2.87 | 1.71 | 3.85 | 5.47 | 0.37 |
| Gewinn je Aktie unverwässert | 3.57 | 1.90 | 2.92 | 1.73 | 3.95 | 5.59 | 0.38 |
| Gewinn je Aktie verwässert | 3.52 | 1.87 | 2.87 | 1.71 | 3.88 | 5.47 | 0.38 |
| Dividende pro Aktie | 1.30 | 1.38 | 1.46 | 1.53 | 1.57 | 1.61 | 1.65 |
| Gesamtdividendenausschüttung in Mio. | 7’659.00 | 7’978.00 | 8’043.00 | 8’440.00 | 8’729.00 | 8’983.00 | 9’247.00 |
Pfizer Inc.: Unternehmenskennzahlen (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 8.67 | 8.98 | 9.12 | 7.44 | 14.24 | 17.50 | 10.25 |
| KGV (Jahresendkurs, EPS unverwässert) | 10.30 | 23.39 | 13.66 | 21.56 | 15.22 | 9.37 | 76.67 |
| KGV (Jahresendkurs, EPS verwässert) | 10.30 | 23.39 | 13.66 | 21.56 | 15.22 | 9.37 | 76.67 |
| KGV (Jahresendkurs) | 10.30 | 23.39 | 13.66 | 21.56 | 15.22 | 9.37 | 76.67 |
| Dividendenrendite Jahresende in % | 3.59 | 3.16 | 3.73 | 4.16 | 2.66 | 3.14 | 5.73 |
| Eigenkapitalquote in % | 41.71 | 39.99 | 37.88 | 41.16 | 42.68 | 48.64 | 39.42 |
| Fremdkapitalquote in % | 58.29 | 60.01 | 62.12 | 58.84 | 57.32 | 51.36 | 60.58 |
Pfizer Inc.: GuV (in Mio. USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 52’546.00 | 53’647.00 | 51’750.00 | 41’908.00 | 81’288.00 | 100’330.00 | 58’496.00 |
| Umsatzveränderung in % | -0.53 | 2.10 | -3.54 | -19.02 | 93.97 | 23.43 | -41.70 |
| Bruttoergebnis vom Umsatz | 36’757.00 | 37’639.00 | 37’011.00 | 29’843.00 | 46’875.00 | 62’090.00 | 29’283.00 |
| Bruttoergebnisveränderung in % | -0.31 | 2.40 | -1.67 | -19.37 | 57.07 | 32.46 | -52.84 |
| Operatives Ergebnis | 14’425.00 | 15’289.00 | 14’117.00 | 9’018.00 | 20’793.00 | 37’549.00 | 4’235.00 |
| Veränderung Operatives Ergebnis in % | 1.06 | 5.99 | -7.67 | -36.12 | 130.57 | 80.58 | -88.72 |
| Ergebnis vor Steuern | 12’305.00 | 11’885.00 | 17’682.00 | 7’497.00 | 24’311.00 | 34’729.00 | 1’058.00 |
| Veränderung Ergebnis vor Steuern in % | 47.35 | -3.41 | 48.78 | -57.60 | 224.28 | 42.85 | -96.95 |
| Ergebnis nach Steuer | 21’306.00 | 11’143.00 | 16’269.00 | 6’985.00 | 22’415.00 | 31’366.00 | 2’133.00 |
| Veränderung Ergebnis nach Steuer in % | 196.00 | -47.70 | 46.00 | -57.07 | 220.90 | 39.93 | -93.20 |
Pfizer Inc.: Bilanz (in Mio. USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 100’141 | 95’664 | 104’044 | 90’756 | 104’013 | 101’288 | 137’213 |
| Langzeit Gesamtverbindlichk. pro Aktie | 11.66 | 11.16 | 12.06 | 11.65 | 10.91 | 10.53 | 15.84 |
| Eigenkapital | 71’656 | 63’758 | 63’445 | 63’473 | 77’463 | 95’917 | 89’288 |
| Veränderung Eigenkapital in % | 19.77 | -11.08 | -0.41 | 0.18 | 22.08 | 23.91 | -6.95 |
| Bilanzsumme | 171’797 | 159’422 | 167’489 | 154’229 | 181’476 | 197’205 | 226’501 |
| Veränderung Bilanzsumme in % | 0.11 | -7.20 | 5.06 | -7.92 | 17.67 | 8.67 | 14.86 |
Pfizer Inc.: Sonstige Angaben (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 3.57 | 1.90 | 2.92 | 1.73 | 3.95 | 5.59 | 0.38 |
| Veränderung Gewinn je Aktie (unverwässert) in % | 202.42 | -46.78 | 53.85 | -40.76 | 128.42 | 41.45 | -93.29 |
| Gewinn je Aktie (verwässert) | 3.52 | 1.87 | 2.87 | 1.71 | 3.88 | 5.47 | 0.38 |
| Veränderung Gewinn je Aktie (verwässert) in % | 200.58 | -46.94 | 53.67 | -40.46 | 127.23 | 41.01 | -93.14 |
| Anzahl Mitarbeiter | 90’200 | 92’400 | 88’300 | 78’500 | 79’000 | 83’000 | 88’000 |
| Veränderung Anzahl Mitarbeiter in % | -6.53 | 2.44 | -4.44 | -11.10 | 0.64 | 5.06 | 6.02 |
Pfizer Inc. Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Pfizer Inc. | Quartalszahlen | 04.02.2025 |
| Pfizer Inc. | Quartalszahlen | 06.05.2025 |
| Pfizer Inc. | Quartalszahlen | 05.08.2025 |
| Pfizer Inc. | Quartalszahlen | 04.11.2025 |
Pfizer Inc. vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 29.10.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 30.07.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 01.05.2024 |
| Hauptversammlung | Annual General Meeting | 25.04.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 30.01.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 31.10.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 01.08.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 02.05.2023 |
| Hauptversammlung | Annual General Meeting | 27.04.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 31.01.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 01.11.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 28.07.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 03.05.2022 |
| Hauptversammlung | Annual General Meeting | 28.04.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 08.02.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.96 |
| The Vanguard Group, Inc. | 8.94 |
| Vanguard Group, Inc. (Subfiler) | 8.65 |
| State Street Corp. | 5.13 |
| SSgA Funds Management, Inc. | 5.08 |
| Vanguard Total Stock Market ETF | 3.17 |
| Wellington Management Co. LLP (Wellington Breakout) | 2.74 |
| BlackRock Fund Advisors | 2.65 |
| Vanguard 500 Index Fund | 2.62 |
| Charles Schwab Investment Management, Inc. | 2.30 |
| BlackRock Institutional Trust Co. NA | 2.21 |
| Geode Capital Management LLC | 2.08 |
| Schwab US Dividend Equity ETF | 1.55 |
| Norges Bank (13F) | 1.48 |
| Massachusetts Financial Services Co. | 1.26 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 88’300 | 78’500 | 79’000 | 83’000 | 88’000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.59 | 0.53 | 1.03 | 1.21 | 0.66 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 32’803 | 35’067 | 59’693 | 51’259 | 43’333 |
| Summe Anlagevermögen | 134’686 | 119’162 | 121’783 | 145’946 | 183’168 |
| Summe Aktiva | 167’489 | 154’229 | 181’476 | 197’205 | 226’501 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 53’474 | 41’271 | 41’395 | 39’046 | 75’041 |
| Summe Fremdkapital | 104’044 | 90’756 | 104’013 | 101’288 | 137’213 |
| Summe Eigenkapital | 63’445 | 63’473 | 77’463 | 95’917 | 89’288 |
| Summe Passiva | 167’489 | 154’229 | 181’476 | 197’205 | 226’501 |
Adresse
| 66 Hudson Boulevard East, 10001-2192 New York | |
| Telefon | +1 (212) 733-2323 |
| URL | http://www.pfizer.com |
Management
|
Aamir Malik
Chief Commercial Officer-US & Executive VP |
|
Aida Habtezion
Chief Medical Officer & Head-Worldwide Medical |
|
Albert Bourla
Chairman & Chief Executive Officer |
|
Alexandre de Germay
Chief International Commercial Officer & EVP |
|
Annaliesa Anderson
SVP, Head-Vaccine Research & Development |
|
Barbara J. Dalton
Vice President-Worldwide Business Development |
|
Berta Rodriguez-Hervas
Chief Artificial Intelligence & Analytics Officer |
|
Bryan Supran
Senior Vice President & Deputy General Counsel |
|
Chris Boshoff
Chief Oncology Officer & Executive Vice President |
|
Christopher J. Stevo
Chief Investor Relations Officer & Senior VP |
|
Cyrus Russi Taraporevala
Non-Executive Director |
|
Dan R. Littman
Independent Director |
|
David M. Denton
Chief Financial Officer & Executive Vice President |
|
Denis Patrick
Executive Director & Vice President-WRDM |
|
Douglas M. Lankler
Executive Vice President & General Counsel |
|
François-Maurice Garnier
International General Counsel |
|
Gordon Loh
Senior Vice President-Corporate Audit |
|
Helen H. Hobbs
Independent Director |
|
James C. Smith
Independent Director |
|
James Quincey
Independent Director |
|
Jeff Settleman
Co-Chief Scientific Officer |
|
Jennifer B. Damico
Senior Vice President & Controller |
|
John DeYoung
Vice President-Worldwide Business Development |
|
Joseph J. Echevarria
Independent Director |
|
Lidia L. Fonseca
Executive VP, Chief Technology & Digital Officer |
|
Luis Jodar
Chief Medical Officer-Vaccines & Senior VP |
|
Margaret M. Madden
Secretary, Chief Governance Counsel & Senior VP |
|
Maria Rivas
Chief Medical Affairs Officer |
|
Markus Green
Vice President & Assistant General Counsel |
|
Michael Mcdermott
Chief Global Supply Officer & Executive VP |
|
Mikael Dolsten
Co-Chief Scientific Officer & President-Research |
|
Mortimer Joseph Buckley
Director |
|
Patrice Ettinger
Chief Privacy Offucer |
|
Payal Sahni Becher
Chief People Experience Officer & Executive VP |
|
Rady A. Johnson
EVP, Chief Compliance, Quality & Risk Officer |
|
Roger D. Dansey
Chief Development Officer-Oncology |
|
Ronald Edward Blaylock
Independent Director |
|
Sally Susman
Chief Corporate Affairs Officer & Executive VP |
|
Scott Gottlieb
Independent Director |
|
Shantanu Narayen
Lead Independent Director |
|
Suneet Varma
President-US Oncology Business Unit |
|
Susan D. Desmond-Hellmann
Independent Director |
|
Susan J. Hockfield
Independent Director |
|
Susan Rienow
Global Chief Marketing Officer |
|
Suzanne Nora Johnson
Independent Director |
|
William C. Sessa
SVP &Chief Scientific Officer-Internal Medicine |